AstraZeneca Deal History & Licensing Activity
AstraZeneca is a large pharma headquartered in UK. Over the past three years, AstraZeneca has been involved in 23 licensing and acquisition transactions, with a primary focus on Other (9 deals). The company currently has 50 active clinical trials, primarily in Solid Tumors.
Deals (12mo)
9
Active Trials
50
Top Modality
Other
Focus Area
Solid Tumors
AstraZeneca Recent Deal Activity
Licensing, acquisition, and partnership transactions involving AstraZeneca in the past 12 months.
| Asset | Partner | Modality | Phase | Type | Date |
|---|---|---|---|---|---|
| companion diagnostics (solid tumor and hematological oncology) | SOPHiA GENETICS | Other | Unknown | collaboration | Aug 4, 2026 |
| Zegfrovy | Dizal Pharmaceutical | Small Molecules | Approved | license | Jul 14, 2026 |
| TQC3721 | Sino Bio | Small Molecules | Preclinical | license | Jul 8, 2026 |
| Kidney disease collaboration program | CSPC | Other | Discovery | collaboration | Jul 2, 2026 |
| lumipodlin (ABSK043) | Abbisko Therapeutics | Small Molecules | Phase 2 | collaboration | Jul 1, 2026 |
| SelectPSMA | Nucs AI | Other | Discovery | collaboration | May 29, 2026 |
| Eight obesity/T2D programs plus AI design and LiquidGel technology | CSPC Pharmaceutical Group | Other | Preclinical | license | Jan 30, 2026 |
| JAB-23E73 | Jacobio Pharma | Small Molecules | Phase 1 | license | Dec 21, 2025 |
| AZD7325 | Axsome Therapeutics, Inc. | Small Molecules | Phase 1 | license | Nov 6, 2025 |
AstraZeneca Pipeline Focus
Therapeutic areas and modalities where AstraZeneca is most active based on deal history and clinical trial data.
Therapeutic Areas
Modalities
AstraZeneca Strategic Signals
Key indicators of AstraZeneca's licensing and acquisition strategy, including patent expirations, pipeline gaps, and strategic priorities.
Strategic Profile
Acquisition Appetite
Strategic Priorities
AstraZeneca Clinical Pipeline
AstraZeneca has 50 active clinical trials across 6 development phases.
2
Unknown
2
Phase 1
8
Phase 1/2
14
Phase 2
1
Phase 2/3
23
Phase 3
See How Your Asset Matches AstraZeneca's Portfolio
Use Solidus to benchmark upfront payments, milestones, and royalties for Solid Tumors assets — powered by data from 3,500+ real biopharma transactions.
Related Intelligence
Oncology Deal Benchmarks
Market sizing, deal terms, and competitive landscape for oncology
Metabolic Deal Benchmarks
Market sizing, deal terms, and competitive landscape for metabolic
Other Benchmarks
Upfront, milestone, and royalty benchmarks for other deals
Small Molecules Benchmarks
Upfront, milestone, and royalty benchmarks for small molecules deals
Deal Pulse
Track the latest biopharma licensing and acquisition deals across all therapeutic areas
All Company Profiles
Browse 700+ biotech and pharma company profiles with deal history and pipeline data
2026 Deal Benchmarks Report
Industry-wide analysis of deal terms, trends, and market dynamics
About AstraZeneca Licensing & Deal Activity
AstraZeneca is a large pharma company based in UK that has been actively engaged in licensing transactions across the biopharma landscape. With 23 deals over the past three years, AstraZeneca ranks among the most acquisitive companies tracked by Ambrosia Ventures.
Key therapeutic areas of focus for AstraZeneca include Solid Tumors (18 deals and trials), Oncology (16 deals and trials), Metabolic (6 deals and trials), and Autoimmune (5 deals and trials). In terms of modality, AstraZeneca has shown particular interest in other, small molecules, small molecules.
Ambrosia Ventures tracks deal terms, pipeline data, patent expirations, and competitive positioning for AstraZeneca and 700+ other biopharma companies. Use our Solidus to benchmark your asset against AstraZeneca's historical deal terms, or explore all company profiles to find the best partner match for your pipeline.